Ministerio DA Saude/central DE Pharmaceutical Import Profile — Mozambique (DGFT 2022–2026)

Name: Ministerio DA Saude/central DE Pharmaceutical Import Records from India — 2 Products, $250.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ministerio DA Saude/central DE — Pharmaceutical Importer Profile (2026) | 2 Products, $250.0K Trade | TransData Nexus

Ministerio DA Saude/central DE

Pharmaceutical Importer · Mozambique · Antiviral & HIV Medications Focus · $250.0K Total Trade · DGFT Verified

Ministerio DA Saude/central DE is a pharmaceutical importer based in Mozambique with a total trade value of $250.0K across 2 products in 1 therapeutic categories. Based on 5 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Ministerio DA Saude/central DE sources from 10 verified Indian suppliers, with Aurobindo Pharma Limited accounting for 21.9% of imports.

Ministerio DA Saude/central DE — Import Portfolio & Supplier Network

Ministerio DA Saude/central DE import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Ministerio DA Saude/central DE?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Aurobindo Pharma Limited	$435.9K	13	21.9%
Biological E. Limited	$300.0K	6	15.1%
Ipca Laboratories Limited	$287.4K

What Formulations Does Ministerio DA Saude/central DE Import?

Formulation	Value	Ships
Diptheria and tetanus (dt)/ tetanus	$150.0K	3
Nevimune oral suspension (nevirapine	$140.9K	3
Nevirapine oral suspension 50MG/5ML-100ML	$117.3K	3
Anzavir-r(atazanavir 300MG + ritonavir	$100.0K	2
Diptheria and tetanus(dt)/tetanus and	$100.0K	2
Dolutegravir+lamivudine+tenofovir disopr50mg+300MG+300MG tablet 30s	$100.0K	2
Lamivudine 300MG + tenofovir disoproxilfumarate 300 MG + dolutegravir 50 MG	$100.0K	2
Harmless medicines-artemether/lumefantri	$98.2K	2
Harmless medicines-artemether/lumefantrine 20MG/120MG dispersible tablets 12x30tablet blister lumerax dt	$89.2K	9
Combiart-dt - artemether/lumefantrine	$85.0K	2
Lopinavir and ritonavir tablets 200 /	$50.0K	1
Lopinavir/ritonavir tablets 100 / 25MG	$50.0K	1
Pharma products(finished product	$50.0K	1
Lopinavir/ritonavir tablets 100 /25MG	$50.0K	1
Lopinavir and ritonavir tablets 200 &	$50.0K	1

Ministerio DA Saude/central DE imports 51 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Dolutegravir	Antiviral & HIV Medications	$150.0K	3	0.0%	13
2	Atazanavir	Antiviral & HIV Medications	$100.0K	2	0.1%	15

Ministerio DA Saude/central DE imports 2 pharmaceutical products across 1 categories into Mozambique totaling $250.0K.

Ministerio DA Saude/central DE — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Ministerio DA Saude/central DE is the central procurement and distribution arm of Mozambique's Ministry of Health, responsible for sourcing and supplying pharmaceutical products to the national healthcare system. As a government entity, it operates under the Ministry of Health's directives, ensuring the availability of essential medicines across the country. Its role is pivotal in maintaining the supply chain for pharmaceuticals, particularly in the public sector, by managing imports, storage, and distribution to various health facilities.

The organization is headquartered in Maputo, Mozambique's capital, and functions as a central hub for pharmaceutical logistics. While it does not have a parent company, its operations are closely aligned with the Ministry of Health's objectives, aiming to provide equitable access to quality healthcare services nationwide. Through its centralized procurement system, Ministerio DA Saude/central DE plays a critical role in the distribution of medicines, ensuring that both urban and rural health facilities receive necessary pharmaceutical supplies.

2Distribution Network

Ministerio DA Saude/central DE's distribution network is designed to ensure the efficient delivery of pharmaceutical products throughout Mozambique. The central warehouse in Maputo serves as the primary storage and distribution point, coordinating the supply of medicines to regional and provincial warehouses. From these regional centers, products are further distributed to hospitals, clinics, and pharmacies across the country, facilitating nationwide coverage.

Logistically, the organization faces challenges due to Mozambique's infrastructure limitations, including inadequate road networks and limited access to electricity in some areas. These factors can impact the timely delivery and quality of pharmaceutical products. To mitigate these issues, Ministerio DA Saude/central DE collaborates with international partners and utilizes pre-qualified suppliers to ensure the reliability and safety of its pharmaceutical imports. The distribution network's effectiveness is crucial for maintaining the stability of the national healthcare system and ensuring that essential medicines are accessible to all citizens.

3Industry Role

As the central procurement and distribution entity under the Ministry of Health, Ministerio DA Saude/central DE holds a dominant position in Mozambique's pharmaceutical supply chain. It functions as the primary wholesaler, sourcing medicines from international suppliers and distributing them to various healthcare facilities nationwide. This centralized approach allows for standardized procurement processes, bulk purchasing advantages, and streamlined distribution, which are essential for managing the country's pharmaceutical needs effectively.

The organization's role extends beyond mere distribution; it is integral to the national health policy implementation, ensuring that the public sector has access to a consistent and reliable supply of essential medicines. By centralizing procurement, Ministerio DA Saude/central DE can negotiate better pricing, monitor inventory levels more effectively, and maintain quality control standards across the healthcare system. This centralized model is particularly important in a country like Mozambique, where resource constraints and logistical challenges can impede the efficient delivery of healthcare services.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Ministerio DA Saude/central DE

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Ministerio DA Saude/central DE's sourcing strategy reveals a high concentration on a limited number of products, with the top five products accounting for 100% of its imports. This indicates a focused procurement approach, likely driven by specific therapeutic needs within the country. The primary products imported are Dolutegravir and Atazanavir, both antiretroviral medications essential for HIV/AIDS treatment.

The concentration on these two products suggests a strategic choice to address the high prevalence of HIV/AIDS in Mozambique. However, this dependency on a narrow product range could pose risks, such as supply chain disruptions or price fluctuations affecting these specific medications. The stability of the relationship with Indian suppliers is crucial, as any issues could significantly impact the availability of these essential drugs. Diversifying the product portfolio and establishing relationships with multiple suppliers could mitigate such risks and enhance the resilience of the supply chain.

2Supply Chain Resilience

The resilience of Ministerio DA Saude/central DE's supply chain is closely tied to its sourcing strategy from Indian pharmaceutical manufacturers. The organization imports finished pharmaceutical formulations, including Dolutegravir and Atazanavir, from a select group of Indian suppliers. This focused sourcing approach can lead to strong partnerships and favorable pricing but also creates vulnerabilities if any single supplier faces production issues or regulatory challenges.

Importing Pharmaceuticals into Mozambique — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Mozambique

1Regulatory Authority & Framework

The pharmaceutical sector in Mozambique is regulated by the Autoridade Nacional Reguladora de Medicamentos de Moçambique (ANARME), established under the Medicines Act of 2017. ANARME is responsible for ensuring the quality, safety, efficacy, and traceability of all pharmaceutical products circulating in the country. This includes overseeing the registration, inspection, and monitoring of medicines, vaccines, and biological products.

The legal framework governing pharmaceutical imports is primarily based on Law 4/98 and Decree 22/99, which outline the requirements for marketing authorization, importation, and distribution of pharmaceutical products. These regulations aim to align Mozambique's pharmaceutical practices with international standards, ensuring that imported medicines meet the necessary quality and safety criteria.

2Import Licensing & GMP

Import licensing in Mozambique requires that pharmaceutical importers obtain authorization from the Ministry of Health. Applicants must submit comprehensive documentation, including proof of qualifications for a Technical Manager, a plan of the establishment, and evidence of compliance with safety and storage requirements for medicines. The licensing process ensures that importers adhere to national standards for pharmaceutical distribution. (apiex.gov.mz)

Ministerio DA Saude/central DE — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Ministerio DA Saude/central DE's focus on importing antiretroviral medications, particularly Dolutegravir and Atazanavir, aligns with Mozambique's high HIV/AIDS prevalence. This strategic emphasis addresses the urgent need for effective HIV treatment options and supports the country's public health objectives. The decision to import these specific therapeutic areas is driven by the demand for affordable and accessible HIV medications to manage the disease burden effectively.

The market demand for these antiretroviral drugs is substantial, given the significant number of individuals requiring long-term HIV management. By focusing on these therapeutic areas, Ministerio DA Saude/central DE aims to provide comprehensive care and improve health outcomes for the population.

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Ministerio DA Saude/central DE

What products does Ministerio DA Saude/central DE import from India?

Ministerio DA Saude/central DE imports 2 pharmaceutical products across 1 categories. Top imports: Dolutegravir ($150.0K), Atazanavir ($100.0K).

Who supplies pharmaceuticals to Ministerio DA Saude/central DE from India?

Ministerio DA Saude/central DE sources from 10 verified Indian suppliers. The primary supplier is Aurobindo Pharma Limited (21.9% of imports, $435.9K).

What is Ministerio DA Saude/central DE's total pharmaceutical import value?

Ministerio DA Saude/central DE's total pharmaceutical import value from India is $250.0K, based on 5 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Ministerio DA Saude/central DE focus on?

Ministerio DA Saude/central DE imports across 1 categories. The largest: Antiviral & HIV Medications (100.0%).

Get Full Ministerio DA Saude/central DE Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.